13.82
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$13.80
Aprire:
$13.76
Volume 24 ore:
974.22K
Relative Volume:
0.58
Capitalizzazione di mercato:
$1.72B
Reddito:
$181.74M
Utile/perdita netta:
$-599.49M
Rapporto P/E:
-2.7585
EPS:
-5.01
Flusso di cassa netto:
$-604.32M
1 W Prestazione:
-6.62%
1M Prestazione:
-27.03%
6M Prestazione:
-29.74%
1 anno Prestazione:
-51.68%
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Nome
Arrowhead Pharmaceuticals Inc
Settore
Industria
Telefono
626-696-4702
Indirizzo
177 E COLORADO BLVD, PASADENA, CA
Confronta ARWR con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ARWR
Arrowhead Pharmaceuticals Inc
|
13.82 | 1.72B | 181.74M | -599.49M | -604.32M | -5.01 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-06-05 | Iniziato | Goldman | Neutral |
2023-12-04 | Iniziato | BofA Securities | Buy |
2023-09-19 | Iniziato | Citigroup | Neutral |
2023-07-21 | Iniziato | TD Cowen | Outperform |
2023-05-12 | Downgrade | SVB Securities | Outperform → Market Perform |
2023-04-26 | Iniziato | SMBC Nikko | Outperform |
2023-04-12 | Aggiornamento | SVB Securities | Market Perform → Outperform |
2023-03-21 | Iniziato | Bernstein | Mkt Perform |
2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
2022-05-11 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
2022-01-19 | Ripresa | Goldman | Buy |
2021-08-06 | Reiterato | Chardan Capital Markets | Buy |
2021-06-04 | Ripresa | Robert W. Baird | Neutral |
2021-02-05 | Reiterato | H.C. Wainwright | Buy |
2020-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
2020-12-16 | Iniziato | UBS | Buy |
2020-11-19 | Iniziato | Citigroup | Buy |
2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
2020-05-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
2020-04-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
2020-03-24 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
2020-03-17 | Iniziato | Goldman | Neutral |
2020-01-21 | Iniziato | SVB Leerink | Underperform |
2019-12-13 | Iniziato | Oppenheimer | Perform |
2019-11-29 | Reiterato | Chardan Capital Markets | Buy |
2019-11-27 | Reiterato | B. Riley FBR | Buy |
2019-11-25 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
2019-10-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
2019-10-22 | Reiterato | Chardan Capital Markets | Buy |
2019-10-03 | Iniziato | Robert W. Baird | Outperform |
2018-09-07 | Aggiornamento | B. Riley FBR | Neutral → Buy |
2018-09-06 | Reiterato | Chardan Capital Markets | Buy |
2018-08-08 | Reiterato | Cantor Fitzgerald | Overweight |
2018-07-02 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
Rnai Technology Market Set to Witness Significant Growth - openPR
Arrowhead stock hits 52-week low at $14.21 amid market challenges - Investing.com Canada
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the company - Yahoo Finance
Arrowhead Pharmaceuticals Is Finally Arriving (NASDAQ:ARWR) - Seeking Alpha
(ARWR) Pivots Trading Plans and Risk Controls - Stock Traders Daily
RNA Therapies Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approval, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight - The Globe and Mail
First Capital REIT Announces March 2025 Distribution - The Globe and Mail
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by US Bancorp DE - Defense World
Bank of New York Mellon Corp Sells 36,341 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead stock holds Buy rating, $80 target from H.C. Wainwright By Investing.com - Investing.com UK
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - AOL
Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 4.2% drop adds to a year losses - Simply Wall St
Buy Rating for Arrowhead Pharmaceuticals Driven by Promising ARO-C3 Trial Results and Strategic Pipeline Advancements - TipRanks
Arrowhead Pharmaceuticals Stock Dips Despite Promising Study - TipRanks
Mutual of America Capital Management LLC Sells 1,519 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy - BioSpace
Arrowhead Pharmaceuticals Says Study for Complement-Mediated Disease Therapy Shows C3 Reduction in Patients - Marketscreener.com
Arrowhead Pharma Reports Positive Topline Data From Phase 1/2 Study Of ARO-C3 - Nasdaq
Arrowhead Pharmaceuticals Announces Topline Results From Part 2 Of Phase 1/2 Study Of Aro-C3 In Patients With IgA Nephropathy - Marketscreener.com
Arrowhead Clinical Trial: 87% C3 Reduction in IgA Nephropathy Patients - StockTitan
Arrowhead Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Arrowhead Pharmaceuticals CEO sells $5.27 million in stock By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases - Lelezard
Arrowhead Pharmaceuticals Presents Data on Two Clinical-Stage Candidates for Obesity Treatment - Marketscreener.com
Arrowhead advances RNAi obesity treatments in clinical trials - Investing.com
Arrowhead advances RNAi obesity treatments in clinical trials By Investing.com - Investing.com UK
Arrowhead Pharmaceuticals CEO sells $5.27 million in stock - Investing.com
Familial Chylomicronemia Syndrome Market to Expand - openPR
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Position Trimmed by Principal Financial Group Inc. - Defense World
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS) - Galveston County Daily News
How Arrowhead's New FCS Resources Could Transform Life for Rare Disease Patients - StockTitan
Rhumbline Advisers Increases Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Objective long/short (ARWR) Report - Stock Traders Daily
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity - The Bakersfield Californian
Can Arrowhead's New Obesity Drug Outperform GLP-1s? Preclinical Data Shows Key Advantage - StockTitan
Van ECK Associates Corp Raises Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Empowered Funds LLC Takes $268,000 Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions (NASDAQ:ARWR) - Seeking Alpha
Fat, not muscle: drugmakers in race for next weight-loss breakthrough - Reuters
Zacks Small Cap Has Pessimistic Outlook of ARWR Q2 Earnings - MarketBeat
Analysts Offer Predictions for ARWR Q2 Earnings - MarketBeat
Arrowhead Pharmaceuticals' SWOT analysis: RNAi pioneer's stock poised for potential breakthrough By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals' SWOT analysis: RNAi pioneer's stock poised for potential breakthrough - Investing.com
Arrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
B. Riley Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat
Guidewire Software set to join S&P MidCap 400; Arrowhead Pharmaceuticals to join S&P SmallCap 600 - MSN
Leerink Partnrs Analysts Raise Earnings Estimates for ARWR - MarketBeat
Arrowhead Pharmaceuticals Inc Azioni (ARWR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):